The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).
 
Mitsuho Imai
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuichiro Tsukada
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Mamoru Uemura
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Akinobu Taketomi
No Relationships to Disclose
 
Takao Fujisawa
Honoraria - Merck Serono
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Motohiro Kojima
No Relationships to Disclose
 
Shohei Koyama
Consulting or Advisory Role - Kaken Pharmaceutical
Research Funding - Otsuka
 
Chiyoon Oum
Employment - Lunit
 
Seunghwan Shin
Employment - Lunit
Stock and Other Ownership Interests - Lunit
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; Medpacto; Y-Biologics
Consulting or Advisory Role - Genome & Company; Idience; Medpacto; PIN therapeutics; Selecxine; Y-Biologics
 
Hiroyoshi Nishikawa
Stock and Other Ownership Interests - Cellian-Biclo; Sustainable Cell Therapeutics
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD K.K; Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; Eisai; Fujifilm; Hitachi; Janssen Research & Development; Kyowa Kirin; MSD K.K.; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; SRL Diagnostics; Sumitomo Dainippon Pharma; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Masaaki Ito
Employment - Asahi Intecc; Jmees Inc.
Stock and Other Ownership Interests - Jmees Inc.
Honoraria - Applied Medical Japan; Bayer Yakuhin; Covidien; Fujifilm; Johnson & Johnson; Kaken Pharmaceutical; MC Medical; Nippon Covidien; Olympus
Consulting or Advisory Role - Asahi Intecc
Research Funding - Astellas Pharma; EBM; Fujifilm; Indivumed; Kawasumi Laboratories; Muranaka Medical Instruments; Nippon Covidien; Olympus; Sumitomo Chemical
Patents, Royalties, Other Intellectual Property - BMG Inc.; EBM; Kotobuki Medical Inc.; Muranaka Medical Instruments; NITION; Olympus; Sumitomo Chemical; Takano Co., Ltd.
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)